Quick Answer
Anika Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $112.82 million for the year ending 2025.
- Anika Therapeutics, Inc. showed a decrease of -5.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Anika Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 9.1%.
- Historical annual values: Fiscal year 2025: $112.82 million | Fiscal year 2024: $119.91 million | Fiscal year 2023: $120.79 million | Fiscal year 2022: $113.83 million | Fiscal year 2021: $147.79 million | Fiscal year 2020: $130.46 million | Fiscal year 2019: $114.61 million | Fiscal year 2018: $105.56 million | Fiscal year 2017: $113.42 million | Fiscal year 2016: $103.38 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: